Are Orphan Drugs Still a Licence to Print Money?
Add bookmark
Are Orphan Drugs Still a Licence to Print Money?
Add bookmark
In this podcast Donald Macarthur, global pharmaceutical business analyst, speaks to Andrea Charles from Pharma IQ, about Pharma's steps into the orphan drug market and whether payers can afford to fund orphan drugs at a time of austerity measures. Macarthur also shares his insights on how reimbursement rules have affected the market and how risk sharing schemes and patient registries can help bridge the data gap. [inlinead]
Tags:
Donald Macarthur
pricing
drug pricing
pharmaceutical pricing
pricing and reimbursement
reimbursement funding
drug pricing Europe
HTA
risk sharing schemes
patient registries
orphan drugs
orphan drug market
rare diseases
